Literature DB >> 9444561

Potentiation of DOI-induced forward locomotion in rats by (-)-pindolol pretreatment.

P Kaur1, S Ahlenius.   

Abstract

The present experiments were undertaken in order to examine mechanisms of action for reported interactions between the beta-blocker (-)-pindolol and serotonergic agents. It was found that pretreatment with (-)-pindolol (2 mg kg-1 s.c.) potentiated the stereotyped forward locomotion induced by the 5-HT2A/C receptor agonist DOI (0.125-1.0 mg kg-1 s.c.) in rats observed in an open-field arena. This (-)-pindolol/DOI-induced stereotyped forward locomotion was fully antagonized by the 5-HT2A/C receptor antagonist ritanserin (2 mg kg-1 s.c.), suggesting that (-)-pindolol enhances serotonin release, resulting i.a. in postsynaptic 5-HT2A/C receptor activation. This effect by (-)-pindolol is in all probability indirect since this compound lacks affinity for 5-HT2A/C receptors, and could be explained by reported antagonism of inhibitory serotonergic somato-dendritic 5-HT1A autoreceptors, although other possibilities related to 5-HT1B receptors or beta-adrenoceptors can not be excluded at this time. Furthermore, (-)-pindolol treatment also enhanced 5-HTP-induced (12.5-100 mg kg-1 i.p.) effects on spontaneous motor activity. These effects, however, were of smaller magnitude, and less consistent than those seen in combination with DOI.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9444561     DOI: 10.1007/BF01291879

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  21 in total

Review 1.  Serotonin receptors: clinical implications.

Authors:  R A Glennon
Journal:  Neurosci Biobehav Rev       Date:  1990       Impact factor: 8.989

2.  8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats.

Authors:  F D Yocca; R N Wright; R R Margraf; A S Eison
Journal:  Pharmacol Biochem Behav       Date:  1990-01       Impact factor: 3.533

Review 3.  Two actions are better than one: avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors.

Authors:  L Romero; N Bel; J M Casanovas; F Artigas
Journal:  Int Clin Psychopharmacol       Date:  1996-09       Impact factor: 1.659

4.  Release of ( 3 H)dopamine by L-5-hydroxytryptophan.

Authors:  L K Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Brain Res       Date:  1972-10-27       Impact factor: 3.252

Review 5.  5-HT-mediated behavior. Animal studies.

Authors:  A R Green
Journal:  Neuropharmacology       Date:  1984-12       Impact factor: 5.250

Review 6.  New players in the 5-HT receptor field: genes and knockouts.

Authors:  J J Lucas; R Hen
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

7.  Photocell measurements of rat motor activity. A contribution to sensitivity and variation in behavioral observations.

Authors:  E Ericson; J Samuelsson; S Ahlenius
Journal:  J Pharmacol Methods       Date:  1991-04

8.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

9.  Striatal dopamine terminals release serotonin after 5-HTP pretreatment: in vivo voltammetric data.

Authors:  J A Stamford; Z L Kruk; J Millar
Journal:  Brain Res       Date:  1990-05-07       Impact factor: 3.252

Review 10.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

View more
  1 in total

1.  Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose.

Authors:  Tomás Pálenícek; Marie Balíková; Vera Bubeníková-Valesová; Jirí Horácek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-07       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.